Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer

Abstract Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and therapeutic targets based on the molecular events dri...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Kirsten G. M. Aspros, Jodi M. Carter, Tanya L. Hoskin, Vera J. Suman, Malayannan Subramaniam, Michael J. Emch, Zhenqing Ye, Zhifu Sun, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Esther P. B. Rodman, Xiyin Wang, Adam W. Nelson, Igor Chernukhin, Feda H. Hamdan, Elizabeth S. Bruinsma, Jason S. Carroll, Martin E. Fernandez-Zapico, Steven A. Johnsen, Krishna R. Kalari, Haojie Huang, Roberto A. Leon-Ferre, Fergus J. Couch, James N. Ingle, Matthew P. Goetz, John R. Hawse
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Portfolio 2022-02-01
Serier:	npj Breast Cancer
Online adgang:	https://doi.org/10.1038/s41523-022-00387-0
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!